Trade
Basic
Futures
Futures
Hundreds of contracts settled in USDT or BTC
TradFi
Gold
Trade global traditional assets with USDT in one place
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Earn
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and enjoy airdrop rewards!
Futures Points
Earn futures points and claim airdrop rewards
Investment
Simple Earn
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Soft Staking
Earn rewards with flexible staking
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-stop lending hub
VIP Wealth Hub
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Quant Fund
Top asset management team helps you profit without hassle
Staking
Stake cryptos to earn in PoS products
Smart Leverage
New
No forced liquidation before maturity, worry-free leveraged gains
GUSD Minting
Use USDT/USDC to mint GUSD for treasury-level yields
More
Trending Topics
View More330.77K Popularity
138.36K Popularity
199.13K Popularity
1.58M Popularity
11.69K Popularity
Pin
Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at Conference
Adrian Gottschalk, CEO of Foghorn Therapeutics, discussed the company’s progress on its Lilly-partnered SMARCA2 program, which is in global Phase 1 trials and is focused on treating NSCLC patients with SMARCA4 loss-of-function mutations. He also highlighted three wholly-owned programs targeting CBP, EP300, and ARID1B, emphasizing the company’s strategy of targeting chromatin remodeling alterations prevalent in many cancers. Gottschalk noted the historical difficulty and limited competition in this therapeutic area due to selectivity challenges, and reiterated the need for high target engagement for effective SMARCA2 inhibition.